A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
Data
2022
Autores
Abreu, Ariane de Jesus Lopes de
Cavalcante, João Roberto
Lagos, Letícia Wigg de Araújo
Caetano, Rosângela
Braga, José Ueleres
Journal Title
Journal ISSN
Volume Title
Publisher
Vaccines
Resumo
We conducted a systematic review and a meta-analysis to assess the risk of serious adverse
events in the elderly after yellow fever vaccination compared to the non-elderly population. We
searched multiple databases and grey literature, and we selected research without language and
publication date restrictions. Studies were analyzed in a descriptive way and meta-analyzed and
expressed in terms of prevalence ratio and risk ratio with a 95% confidence interval, depending on
the degree of heterogeneity found. A total of 18 studies were included and 11 were meta-analyzed.
The results obtained through the meta-analysis showed a risk of serious adverse events after yellow
fever vaccination three times higher for the elderly when compared to the non-elderly popula-
tion and five times higher for persons > 70 years. In relation to adverse event types, viscerotropic
disease associated with the yellow fever vaccine had a risk that was six times higher when com-
pared to the population < 60 years. The evidence found supports that the vaccine indication in
individuals > 60 years of age should be based on a careful analysis of individual benefit-risk assess-
ments. The results found suggest a higher risk of events for individuals > 70 years, especially for
viscerotropic and neurotropic disease associated with YFV contraindicating the use of the YFV in this
age group.
Description
Palavras-chave
yellow fever vaccine, adverse events, systematic review, aged.
Citação
de Abreu AJL, Cavalcante JR, de Araújo Lagos LW, Caetano R, Braga JU. A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population. Vaccines (Basel). 2022 Apr 30;10(5):711. doi: 10.3390/vaccines10050711.